Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Nucl Med Biol. 2014 Dec 23;42(4):375–380. doi: 10.1016/j.nucmedbio.2014.12.012

Figure 1. Specificity of 111In-DTPA-5A10 uptake and dose escalation in NMRI-nu mice.

Figure 1

A. A significant decrease in the tumor-bound activity was seen when co-administered 800 μg non-labeled antibody with 111In-DTPA-5A10. The tumor-bound activity was 36.6 ± 16.4 %IA/g for administration of 111In-DTPA-5A10 alone and 16.4 ± 6.4 %IA/g for co-administration. Tissues were harvested at 48 h post-injection. B. A significantly lower uptake (P < 0.05) is shown in non-PSA-expressing DU145 xenografts, compared to LNCaP xenografts. Increased antibody mass from 20 μg to 50 μg did not significantly alter tissue bio-distribution in LNCaP xenografts. Tissues were harvested at 72 h post-injection.